Patents by Inventor Douglas Hanahan

Douglas Hanahan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination therapy of PD-1-targeted IL-2 variant immunocytokines and antibodies against human PD-L1
    Patent number: 11865082
    Abstract: The present invention relates to the combination therapy of specific PD-1-targeted IL-2 variant immunocytokines with specific antibodies which bind human PD-L1.
    Type: Grant
    Filed: September 1, 2021
    Date of Patent: January 9, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Laura Codarri Deak, Douglas Hanahan, Christian Klein, Valeria Nicolini, Pablo Umana, Stephan Wullschleger
  • FMRP AND CANCER TREATMENT
    Publication number: 20230227823
    Abstract: The present invention provides compositions and methods for down-modulating the expression and/or the immuno-suppressive activity of i) the FMRP protein, ii) an mRNA encoding the FMRP protein, and/or iii) the FMR1 gene for the treatment and/or prevention of primary cancer and/or cancer metastasis in a subject in need thereof.
    Type: Application
    Filed: October 17, 2022
    Publication date: July 20, 2023
    Inventors: Qiqun Zeng, Douglas Hanahan
  • RECOMBINANT VACCINIA VIRUS
    Publication number: 20230201283
    Abstract: The present disclosure provides a replication-competent, recombinant oncolytic vaccinia virus (RVV), compositions comprising the RVV, and use of the RVV or composition for inducing oncolysis in an individual having a tumor.
    Type: Application
    Filed: January 5, 2021
    Publication date: June 29, 2023
    Inventors: Joseph John Binder, Michael Dale Eisenbraun, Douglas Hanahan, David H. Kirn, Clare Lees, Prajit Limsirichai, Liliana Maruri Avidal
  • Recombinant vaccinia virus and methods of use thereof
    Patent number: 11529402
    Abstract: The present disclosure provides a replication-competent, recombinant oncolytic vaccinia virus; and compositions comprising the replication-competent, recombinant oncolytic vaccinia virus. The present disclosure also provides use of the vaccinia virus or composition for inducing oncolysis in an individual having a tumor.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: December 20, 2022
    Assignee: Ignite Immunotherapy, Inc.
    Inventors: Douglas Hanahan, David H. Kirn, Liliana Maruri Avidal, Michael D. Eisenbraun, Joseph J. Binder, Clare Lees
  • FMRP and cancer treatment
    Patent number: 11473087
    Abstract: The present invention provides compositions and methods for down-modulating the expression and/or the immuno-suppressive activity of i) the FMRP protein, ii) an mRNA encoding the FMRP protein, and/or iii) the FMR1 gene for the treatment and/or prevention of primary cancer and/or cancer metastasis in a subject in need thereof.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: October 18, 2022
    Assignee: ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)
    Inventors: Qiqun Zeng, Douglas Hanahan
  • Combination therapy of PD-1-targeted IL-2 variant immunocytokines and antibodies against human PD-L1
    Publication number: 20220072103
    Abstract: The present invention relates to the combination therapy of specific PD-1-targeted IL-2 variant immunocytokines with specific antibodies which bind human PD-L1.
    Type: Application
    Filed: September 1, 2021
    Publication date: March 10, 2022
    Inventors: Laura CODARRI DEAK, Douglas Hanahan, Christian Klein, Valeria Nicolini, Pablo Umana, Stephen Wullschleger
  • FMRP and Cancer Treatment
    Publication number: 20200354718
    Abstract: The present invention provides compositions and methods for down-modulating the expression and/or the immuno-suppressive activity of i) the FMRP protein, ii) an mRNA encoding the FMRP protein, and/or iii) the FMR1 gene for the treatment and/or prevention of primary cancer and/or cancer metastasis in a subject in need thereof.
    Type: Application
    Filed: May 6, 2020
    Publication date: November 12, 2020
    Inventors: Qiqun Zeng, Douglas Hanahan
  • RECOMBINANT VACCINIA VIRUS AND METHODS OF USE THEREOF
    Publication number: 20200222520
    Abstract: The present disclosure provides a replication-competent, recombinant oncolytic vaccinia virus; and compositions comprising the replication-competent, recombinant oncolytic vaccinia virus. The present disclosure also provides use of the vaccinia virus or composition for inducing oncolysis in an individual having a tumor.
    Type: Application
    Filed: January 9, 2020
    Publication date: July 16, 2020
    Applicant: Ignite Immunotherapy, Inc.
    Inventors: Douglas Hanahan, David H. Kirn, Liliana Maruri Avidal, Michael D. Eisenbraun, Joseph J. Binder, Clare Lees
  • COLORECTAL CANCER CLASSIFICATION WITH DIFFERENTIAL PROGNOSIS AND PERSONALIZED THERAPEUTIC RESPONSES
    Publication number: 20150354009
    Abstract: The present invention relates to gene sets, the expression levels of which are useful for classifying colorectal tumors and predicting disease-free prognosis and response of patients to specific therapies that are either novel or currently available in the clinics for colorectal cancer patients.
    Type: Application
    Filed: November 26, 2013
    Publication date: December 10, 2015
    Inventors: Anguraj SADANANDAM, Costas LYSSIOTIS, Douglas HANAHAN, Joe GRAY
  • Lymphatic zip codes in tumors and pre-malignant lesions
    Patent number: 8951971
    Abstract: Disclosed herein are compositions and methods for and involving selectively targeting tumor lymphatics.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: February 10, 2015
    Assignees: Sanford-Burnham Medical Research Institute, The Regents of the University of California
    Inventors: Erkki Ruoslahti, Lianglin Zhang, Douglas Hanahan
  • LYMPHATIC ZIP CODES IN TUMORS AND PRE-MALIGNANT LESIONS
    Publication number: 20140220106
    Abstract: Disclosed herein are compositions and methods for and involving selectively targeting tumor lymphatics.
    Type: Application
    Filed: September 13, 2013
    Publication date: August 7, 2014
    Applicants: The Regents of the University of California, Sanford-Burnham Medical Research Institute
    Inventors: Erkki Ruoslahti, Lianglin Zhang, Douglas Hanahan
  • Molecules that selectively home to vasculature of pre-malignant dysplastic lesions or malignancies
    Patent number: 8598316
    Abstract: The present invention provides a conjugate that contains a therapeutic moiety linked to a homing peptide or peptidomimetic which selectively homes to vasculature of pre-malignant dysplastic skin and which includes the amino acid sequence SRPRR (SEQ ID NO: 1) or a conservative variant or peptidomimetic thereof. The present invention further provides a conjugate containing a therapeutic moiety linked to a homing peptide or peptidomimetic which selectively homes to vasculature of malignant skin and which includes the amino acid sequence CGKRK (SEQ ID NO: 6) or the amino acid sequence CDTRL (SEQ ID NO: 7), or a conservative variant or peptidomimetic of one of these sequences.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: December 3, 2013
    Assignees: Sanford-Burnham Medical Research Institute, The Regents of the University of California
    Inventors: Douglas Hanahan, Erkki Ruoslahti
  • Lymphatic zip codes in tumors and pre-malignant lesions
    Patent number: 8536132
    Abstract: Disclosed herein are compositions and methods for and involving selectively targeting tumor lymphatics.
    Type: Grant
    Filed: February 10, 2011
    Date of Patent: September 17, 2013
    Assignees: Sanford-Burnham Medical Research Institute, The Regents of the University of California
    Inventors: Erkki Ruoslahti, Lianglin Zhang, Douglas Hanahan
  • LYMPHATIC ZIP CODES IN TUMORS AND PRE-MALIGNANT LESIONS
    Publication number: 20110212162
    Abstract: Disclosed herein are compositions and methods for and involving selectively targeting tumor lymphatics.
    Type: Application
    Filed: February 10, 2011
    Publication date: September 1, 2011
    Inventors: Erkki Ruoslahti, Lianglin Zhang, Douglas Hanahan
  • Lymphatic zip codes in tumors and pre-malignant lesions
    Patent number: 7919466
    Abstract: Disclosed herein are compositions and methods for and involving selectively targeting tumor lymphatics.
    Type: Grant
    Filed: February 1, 2007
    Date of Patent: April 5, 2011
    Assignees: The Regents of the University of California, Sanford-Burnham Medical Research Institute
    Inventors: Erkki Ruoslahti, Lianglin Zhang, Douglas Hanahan
  • MOLECULES THAT SELECTIVELY HOME TO VASCULATURE OF PRE-MALIGNANT DYSPLASTIC LESIONS OR MALIGNANCIES
    Publication number: 20110002848
    Abstract: The present invention provides a conjugate that contains a therapeutic moiety linked to a homing peptide or peptidomimetic which selectively homes to vasculature of pre-malignant dysplastic skin and which includes the amino acid sequence SRPRR (SEQ ID NO: 1) or a conservative variant or peptidomimetic thereof. The present invention further provides a conjugate containing a therapeutic moiety linked to a homing peptide or peptidomimetic which selectively homes to vasculature of malignant skin and which includes the amino acid sequence CGKRK (SEQ ID NO: 6) or the amino acid sequence CDTRL (SEQ ID NO: 7), or a conservative variant or peptidomimetic of one of these sequences.
    Type: Application
    Filed: March 26, 2010
    Publication date: January 6, 2011
    Applicants: BURNHAM INSTITUTE FOR MEDICAL RESEARCH, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: DOUGLAS HANAHAN, ERKKI RUOSLAHTI
  • Prefoldin 4 in the treatment and diagnosis of cancer
    Patent number: 7785813
    Abstract: This invention provides methods employing prefoldin-4 (PFDN-4) nucleic acid and polypeptide sequences to detect cancer or a propensity to develop cancer, to monitor the efficacy of a cancer treatment, and/or for prognostic applications. Further, the invention provides methods of identifying inhibitors of PfDN-4 and methods of treating cancer by inhibiting the expression and/or activity of PFDN-4.
    Type: Grant
    Filed: June 19, 2006
    Date of Patent: August 31, 2010
    Assignee: Regents of the University of California
    Inventors: Joe Gray, Graeme Hodgson, Douglas Hanahan, Jeffrey Hager, Oriol Casanovas
  • Molecules that selectively home to vasculature of pre-malignant dysplastic lesions or malignancies
    Patent number: 7723474
    Abstract: The present invention provides a conjugate that contains a therapeutic moiety linked to a homing peptide or peptidomimetic which selectively homes to vasculature of pre-malignant dysplastic skin and which includes the amino acid sequence SRPRR (SEQ ID NO: 1) or a conservative variant or peptidomimetic thereof. The present invention further provides a conjugate containing a therapeutic moiety linked to a homing peptide or peptidomimetic which selectively homes to vasculature of malignant skin and which includes the amino acid sequence CGKRK (SEQ ID NO: 6) or the amino acid sequence CDTRL (SEQ ID NO: 7), or a conservative variant or peptidomimetic of one of these sequences.
    Type: Grant
    Filed: October 20, 2004
    Date of Patent: May 25, 2010
    Assignees: The Regents of the University of California, Burnham Institute for Medical Research
    Inventors: Douglas Hanahan, Erkki Ruoslahti
  • MOLECULES THAT SELECTIVELY HOME TO VASCULATURE OF PREMALIGNANT OR MALIGNANT LESIONS OF THE PANCREAS AND OTHER ORGANS
    Publication number: 20100076175
    Abstract: The invention provides a conjugate that includes a therapeutic moiety linked to a peptide or peptidomimetic that selectively homes to vasculature of premalignant pancreas. The peptide or peptidomimetic contains at least 5 contiguous amino acids of an amino acid sequence selected from CRSRKG (SEQ ID NO:9) and CEYQLDVE (SEQ ID NO:34), or a conservative variant or peptidomimetic thereof. The invention additionally provides a conjugate containing a therapeutic moiety linked to a peptide or peptidomimetic that selectively homes to pancreatic tumor cells and pancreatic tumor vasculature, the peptide or peptidomimetic comprising at least 5 contiguous amino acids of an amino acid sequence selected from CKAAKNK (SEQ ID NO:15), CKGAKAR (SEQ ID NO:19), and VGVGEWSV (SEQ ID NO:35), or a conservative variant or peptidomimetic thereof.
    Type: Application
    Filed: September 14, 2009
    Publication date: March 25, 2010
    Applicants: BURNHAM INSTITUTE FOR MEDICAL RESEARCH, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Douglas Hanahan, Erkki Ruoslahti, Johanna A. Joyce, Pirjo Laakkonen
  • Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs
    Patent number: 7598341
    Abstract: The invention provides a conjugate that includes a therapeutic moiety linked to a peptide or peptidomimetic that selectively homes to vasculature of premalignant pancreas. The peptide or peptidomimetic contains at least 5 contiguous amino acids of an amino acid sequence selected from CRSRKG (SEQ ID NO:9) and CEYQLDVE (SEQ ID NO:34), or a conservative variant or peptidomimetic thereof. The invention additionally provides a conjugate containing a therapeutic moiety linked to a peptide or peptidomimetic that selectively homes to pancreatic tumor cells and pancreatic tumor vasculature, the peptide or peptidomimetic comprising at least 5 contiguous amino acids of an amino acid sequence selected from CKAAKNK (SEQ ID NO:15), CKGAKAR (SEQ ID NO:19), and VGVGEWSV (SEQ ID NO:35), or a conservative variant or peptidomimetic thereof.
    Type: Grant
    Filed: October 29, 2004
    Date of Patent: October 6, 2009
    Assignees: Burnham Institue for Medical Research, The Regents of the Universtiy of California
    Inventors: Douglas Hanahan, Erkki Ruoslahti, Johanna A. Joyce, Pirjo Laakkonen